Overview

Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed

Trial end date:
2010-11-29

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the efficacy of SPD489 compared to placebo on executive function (self-regulation) behaviors in adults with ADHD who report clinically significant impairment of executive function behavior in their everyday environment, as measured by the self-report Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Global Executive Composite (GEC) T-score.

Phase:

Phase 4

Details

Lead Sponsor:

Shire

Treatments:

Lisdexamfetamine Dimesylate